Chiltern Announces New Legal Entity in Israel
Chiltern International Limited (Chiltern), a global clinical contract research organization (CRO), announced that the company has established a new legal entity in Israel.
“Chiltern has experienced a healthy number of requests from our clients in this region and forming a legal entity is a natural progression to our work there,” commented Armand Czaplinski, Chiltern’s Executive Director, Global Country Management, who will be leading the effort in Israel. “Israel is an attractive location to conduct clinical trials as it has many key opinion leaders (KOL) in clinical research and outstanding quality of research. Israel has some of the most skilled and educated work forces with the highest number of doctors, scientists, and engineers per capita than any other country. Another key advantage is that the majority of Israel’s population belongs to the same health maintenance organization and this facilitates quick start for clinical trials and reduces the overall project timelines.”
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
